Table II.
Univariate analyses of association between BRAF-V600E mutation status and clinicopathological parameters in ≥55-age group.
| BRAF-V600E | |||||
|---|---|---|---|---|---|
| Patients' parameters | Total | Mutation | Wild-type | Odds ratio (95% CI) | P-value |
| Age, years (mean ± standard deviation) | 65±9 | 65±8 | 65±9 | NA | 0.976 |
| Sex, n | |||||
| Female | 103 | 51 | 52 | 1 | 0.546 |
| Male | 54 | 24 | 30 | 0.816 (0.421–1.580) | |
| Ethnicity category, n | |||||
| Caucasian | 107 | 57 | 50 | 1 | 0.428b |
| Asian | 9 | 5 | 4 | 1.096 (0.279–4.309) | |
| Black | 11 | 3 | 8 | 0.329 (0.083–1.308) | |
| Tumor size, cm (mean ± standard deviation) | 1.9±1.0 | 1.7±0.9 | 2.1±1.1 | NA | 0.036a |
| Tumor foci, n | |||||
| Unifocality | 85 | 46 | 39 | 1 | 0.136 |
| Multifocality | 69 | 29 | 40 | 0.615 (0.324–1.167) | |
| Lymphocytic thyroiditis, n | |||||
| No | 116 | 59 | 57 | 1 | 0.784 |
| Yes | 21 | 10 | 11 | 0.878 (0.346–2.227) | |
| Histology, n | |||||
| CPTC | 106 | 53 | 53 | 1 | <0.001a |
| FVPTC | 33 | 7 | 26 | 0.269 (0.108–0.674) | |
| TCPTC | 18 | 15 | 3 | 5.000 (1.367–18.287) | |
| Lymph nodes positivity, n (>5) | |||||
| No | 93 | 46 | 47 | 1 | 0.231 |
| Yes | 22 | 14 | 8 | 1.788 (0.685–4.665) | |
| ETE, n (gross) | |||||
| No | 134 | 63 | 71 | 1 | 0.169 |
| Yes | 17 | 11 | 6 | 2.066 (0.722–5.910) | |
| Residual tumor, n | |||||
| No | 110 | 51 | 59 | 1 | 0.111 |
| Yes | 25 | 16 | 9 | 2.057 (0.837–5.051) | |
| RAI therapy, n | |||||
| No | 61 | 35 | 26 | 1 | 0.051 |
| Yes | 83 | 34 | 49 | 0.515 (0.264–1.007) | |
| RAI dose, mCi (mean ± standard deviation) | 122±52 | 125±20 | 102±62 | NA | 0.032a |
| Recurrence follow-up, months | 19 (12–34) | 21 (12–47) | 18 (12-28.3) | NA | 0.018a |
| Recurrence, n | |||||
| No | 132 | 58 | 74 | 1 | 0.031a |
| Yes | 15 | 11 | 4 | 3.509 (1.062–11.590) | |
| Mortality follow-up, months | 20 (13–35) | 25 (14–48) | 18 (12.5–27.5) | NA | 0.006a |
| Mortality, n | |||||
| No | 143 | 66 | 77 | 1 | 0.236 |
| Yes | 14 | 9 | 5 | 1.968 (0.631–6.136) | |
| Recurrence risk stage, n | |||||
| Low | 54 | 9 | 45 | 1 | <0.001a |
| Intermediate | 58 | 42 | 16 | 13.125 (5.238–32.887) | |
| High | 39 | 24 | 15 | 8.000 (3.052–20.967) | |
| T stage, nc | |||||
| 1 | 85 | 32 | 53 | 1 | 0.036a,b |
| 2 | 37 | 22 | 15 | 2.429 (1.103–5.349) | |
| 3 | 27 | 15 | 12 | 2.070 (0.861–4.975) | |
| 4 | 8 | 6 | 2 | 4.969 (0.945–26.116) | |
| N stage, nc | |||||
| 0 | 84 | 36 | 48 | 1 | 0.036a |
| 1a | 18 | 13 | 5 | 3.467 (1.133–10.606) | |
| 1b | 26 | 16 | 10 | 2.133 (0.867–5.250) | |
| M stage, nc | |||||
| 0 | 88 | 44 | 44 | 1 | 1.000b |
| 1 | 5 | 3 | 2 | 1.500 (0.239–9.420) | |
| AJCC stage, nc | |||||
| I/II | 143 | 64 | 79 | 1 | 0.016a |
| III/IV | 14 | 11 | 3 | 0.938 (0.131–6.744) | |
Recurrence/mortality follow-up (months) were described by median or interquartile range. Low recurrence risk, intrathyroidal differentiated thyroid cancer and ≤5 LN micrometastases (<0.2 cm); intermediate recurrence risk, aggressive histology, minor ETE, vascular invasion, or >5 involved lymph nodes (0.2–3 cm); high recurrence risk, gross ETE, incomplete tumor resection, distant metastases or lymph node>3 cm. CPTC, conventional papillary thyroid cancer; CI, confidence intervals; FVPTC, follicular variant papillary thyroid cancer; TCPTC, tall cell variant papillary thyroid cancer; ETE; extrathyroidal extension; RAI, radioactive iodine; T, tumor size; N, lymph node; M, metastasis; AJCC staging, 8th edition American Joint Committee on Cancer staging. aP<0.05; bFisher's exact test; c(11).